SCHEMBL23639746

SCHEMBL23639746

CCCC(C)(C)CCOCCOCCC(=O)N(C)CCC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22021693 0.90 — —
SCHEMBL22166529 0.90 — —
SCHEMBL23639750 0.88 NR1I2 (0.31) —
SCHEMBL22021684 0.88 — —
SCHEMBL22021682 0.88 — —
SCHEMBL22166528 0.88 — —
SCHEMBL22021657 0.88 — —
SCHEMBL22022270 0.86 — —
SCHEMBL22022271 0.85 — —
SCHEMBL22166537 0.77 TDP1 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210213012-A1 COMBINATIONS OF ESTROGEN RECEPTOR DEGRADERS AND CYCLIN-DEPENDENT KINASE INHIBITORS FOR TREATING CANCER ACCUTAR BIOTECHNOLOGY INC. 2021-07-15 — — US disclosed
Send feedback